CTLA4 and melanoma: In melanoma patients treated with ICIs including anti‐CTLA4‐antibody and anti‐PD‐1 antibody, high pretreatment levels of serum sPD‐L1 were associated with an increased likelihood of progressive disease in patients treated with ICIs.34